DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript Summary
DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript Summary
The third quarter demonstrated minimal financial impact from hurricane-related disruptions, with an estimated Q4 impact of approximately $10 million to $20 million.The following is a summary of the DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript:
以下是德維特公司(DVA)2024年第三季度業績會實錄摘要:
Financial Performance:
金融業績：
Adjusted operating income for Q3 was $535 million.
Adjusted EPS for Q3 was $2.59.
The third quarter demonstrated minimal financial impact from hurricane-related disruptions, with an estimated Q4 impact of approximately $10 million to $20 million.
第三季度調整後營業收入爲53500萬美元。
第三季度調整後每股收益爲2.59美元。
第三季度表現出的颶風相關干擾對財務影響較小，預計四季度影響約爲1,000萬至2,000萬美元。
Business Progress:
業務進展：
DaVita managed operational challenges and supply chain disruptions effectively during the hurricane season.
The company continues to focus on operational efficiencies and expansion in integrated kidney care and international markets.
Despite challenges, DaVita remains confident in continuing their growth trajectory into 2025.
德維特在颶風季有效管理運營挑戰和供應鏈中斷。
公司繼續專注於運營效率，並在綜合腎臟護理和國際市場擴展方面取得進展。
儘管存在挑戰，德維特依然對自己能夠持續增長到2025年充滿信心。
Opportunities:
機會：
DaVita's ongoing focus on operational efficiencies and market expansion.
The anticipated regulatory transition regarding oral-only drugs could provide more comprehensive access to therapies, potentially boosting patient outcomes and operational efficiency.
德維特持續關注運營效率和市場擴張。
有關口服藥物的預期監管轉變可能提供更全面的療法，潛在地提升患者結果和運營效率。
Risks:
風險：
Supply chain disruptions from hurricane damages, particularly affecting the availability of peritoneal dialysis solutions and saline, resulting in a temporary suspension of new patient starts on PD and an estimated impact of $10 million to $20 million in Q4.
受颶風破壞引起的供應鏈中斷，尤其影響腹膜透析液和生理鹽水的供應，導致腹透新患者暫時停止接納，預計在第四季度將造成1000萬 2000萬美元的影響。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
